Literature DB >> 3426922

Pharmacokinetic studies with zinc(II)-phthalocyanine in tumour-bearing mice.

E Reddi1, G Lo Castro, R Biolo, G Jori.   

Abstract

Zn(II)-phthalocyanine (Zn-Pc) incorporated into unilamellar liposomes of dipalmitoylphosphatidylcholine has been injected intraperitoneally (0.5 mg kg-1) to BALB/c mice bearing a transplanted MS-2 fibrosarcoma. The drug is specifically transported by serum lipoproteins and cleared from the serum via the bile-gut pathway in a biphasic process: approximately 60% of Zn-Pc is eliminated with a serum half-life of approximately 9 hours, while the remaining aliquot is eliminated at a very slow rate. Several normal tissues take up the drug within 3 hours after administration but release it almost completely after 24-48 hours. On the other hand, the tumour shows a maximum concentration of Zn-Pc (approximately 0.6 microgram g-1 of tissue) after 18-24 hours; at this time, the ratio between the Zn-Pc levels in the tumour and the muscle (which represents the surrounding normal tissue) is approximately 7.5. The results are discussed in terms of a possible use of Zn-Pc as a photosensitizer in the photodynamic therapy of tumours.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3426922      PMCID: PMC2001878          DOI: 10.1038/bjc.1987.247

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  19 in total

1.  Hematoporphyrin as a photosensitizer of tumors.

Authors:  T J Dougherty
Journal:  Photochem Photobiol       Date:  1983-09       Impact factor: 3.421

Review 2.  Photodynamic therapy (PDT) of malignant tumors.

Authors:  T J Dougherty
Journal:  Crit Rev Oncol Hematol       Date:  1984       Impact factor: 6.312

3.  Synthesis, tissue distribution and tumor uptake of 99mTc- and 67Ga-tetrasulfophthalocyanine.

Authors:  J Rousseau; H Ali; G Lamoureux; E Lebel; J E van Lier
Journal:  Int J Appl Radiat Isot       Date:  1985-09

4.  Coated pits, coated vesicles, and receptor-mediated endocytosis.

Authors:  J L Goldstein; R G Anderson; M S Brown
Journal:  Nature       Date:  1979-06-21       Impact factor: 49.962

5.  In situ labelling of vascular endothelium with fluorescent acetylated low density lipoprotein.

Authors:  P A Netland; B R Zetter; D P Via; J C Voyta
Journal:  Histochem J       Date:  1985-12

6.  The phthalocyanines: a new class of mammalian cells photosensitizers with a potential for cancer phototherapy.

Authors:  E Ben-Hur; I Rosenthal
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1985-02

7.  Zinc tetrasulphophthalocyanine as a photodynamic sensitizer for biomolecules.

Authors:  J D Spikes; J C Bommer
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1986-07

8.  Evidence for a major role of plasma lipoproteins as hematoporphyrin carriers in vivo.

Authors:  G Jori; M Beltramini; E Reddi; B Salvato; A Pagnan; L Ziron; L Tomio; T Tsanov
Journal:  Cancer Lett       Date:  1984-10       Impact factor: 8.679

9.  Elimination pathway of hematoporphyrin from normal and tumor-bearing rats.

Authors:  L Tomio; P L Zorat; G Jori; E Reddi; B Salvato; L Corti; F Calzavara
Journal:  Tumori       Date:  1982-08

10.  Cell uptake, distribution and response to aluminium chloro sulphonated phthalocyanine, a potential anti-tumour photosensitizer.

Authors:  W S Chan; R Svensen; D Phillips; I R Hart
Journal:  Br J Cancer       Date:  1986-02       Impact factor: 7.640

View more
  14 in total

Review 1.  Recent applications of phthalocyanines and naphthalocyanines for imaging and therapy.

Authors:  Yumiao Zhang; Jonathan F Lovell
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-07-20

Review 2.  Photonanomedicine: a convergence of photodynamic therapy and nanotechnology.

Authors:  Girgis Obaid; Mans Broekgaarden; Anne-Laure Bulin; Huang-Chiao Huang; Jerrin Kuriakose; Joyce Liu; Tayyaba Hasan
Journal:  Nanoscale       Date:  2016-06-20       Impact factor: 7.790

3.  Photosensitized destruction of human bladder carcinoma cells treated with chlorin e6-conjugated microspheres.

Authors:  R Bachor; C R Shea; R Gillies; T Hasan
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

4.  Use of photosensitive, antibody directed liposomes to destroy target populations of cells in bone marrow: a potential purging method for autologous bone marrow transplantation.

Authors:  J Morgan; A J MacRobert; A G Gray; E R Huehns
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640

5.  Liposome-delivered Si(IV)-naphthalocyanine as a photodynamic sensitiser for experimental tumours: pharmacokinetic and phototherapeutic studies.

Authors:  V Cuomo; G Jori; B Rihter; M E Kenney; M A Rodgers
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

6.  Tumour-localising and -photosensitizing properties of liposome-delivered Ge(IV)-octabutoxy-phthalocyanine.

Authors:  V Cuomo; G Jori; B Rihter; M E Kenney; M A Rodgers
Journal:  Br J Cancer       Date:  1991-07       Impact factor: 7.640

7.  Liposome- or LDL-administered Zn (II)-phthalocyanine as a photodynamic agent for tumours. I. Pharmacokinetic properties and phototherapeutic efficiency.

Authors:  E Reddi; C Zhou; R Biolo; E Menegaldo; G Jori
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

8.  Specific targeting and toxicity of sulphonated aluminium phthalocyanine photosensitised liposomes directed to cells by monoclonal antibody in vitro.

Authors:  J Morgan; A G Gray; E R Huehns
Journal:  Br J Cancer       Date:  1989-03       Impact factor: 7.640

9.  CGP 55398, a liposomal Ge(IV) phthalocyanine bearing two axially ligated cholesterol moieties: a new potential agent for photodynamic therapy of tumours.

Authors:  A Segalla; C Milanesi; G Jori; H G Capraro; U Isele; K Schieweck
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

10.  In vivo fluorescence and photodynamic activity of zinc phthalocyanine administered in liposomes.

Authors:  H L van Leengoed; V Cuomo; A A Versteeg; N van der Veen; G Jori; W M Star
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.